Tyrosine kinase inhibitorFDA-approvedSecond-line
Alectinib
How it works
Blocks the anaplastic lymphoma kinase (ALK) on cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— ALK-positive
Efficacy
Studies show that patients with ALK-positive non-small cell lung cancer who received Alectinib had a response rate of approximately 70%.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Comparing Two Cancer Treatments in Lung Cancer Patients | Lung Cancer | observational | The 3-year progression-free survival rate was 51.5% for brigatinib and 62.1% for alectinib. | Source → |
| Researchers Report a Rare Case of Cancer Remission in Stage IV Lung Cancer Patient | Lung Cancer | observational | — | Source → |
| Combining Cancer Treatments Increases Risk of Lung Damage | Lung Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.